Orlucent® Demonstrates Accurate, Non-Invasive Detection In Vivo of Melanoma-Related Activity Using First-in-Kind Handheld Imaging System

January 16, 2024

Orlucent® Demonstrates Accurate, Non-Invasive Detection In Vivo of Melanoma-Related Activity Using First-in-Kind Handheld Imaging System

LOS GATOS, Calif., January 16, 2024/PRNewswire/ — Researchers at Orlucent, Inc. have demonstrated the use of a novel handheld point-of-care Skin Fluorescence Imaging (SFI) System to noninvasively identify and clinically assess the presence of biological tissue remodeling activity associated with the development of melanoma in adults. The molecular Skin Fluorescence Imaging (mSFI) technology has the potential to greatly improve the assessment of moles—also known as nevi—as well as the selection of which nevi are concerning and may be candidates for biopsy.